- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07312981
The CPH-MBD Cohort Dietary Substudy - Comparison of Methods for Dietary Registrations
December 17, 2025 updated by: University of Copenhagen
The CPH-MBD Cohort - Substudy on Dietary History
The aim of the study is to assess the association between the calcium and phosphorus balance and the stage of kidney disease measured by creatinine clearence in patients with chronic kidney disease stage 4 and 5.
The balance is measured a measurement between the recorded diatery intake and the urinary excretion.
Additionally a comparison between image based diatery accessment and weighted records will be measured
Study Overview
Status
Recruiting
Detailed Description
All participants will be asked to take photos of all the food and fluids they consume during 24 hours.
Additionally participants will be offered to weight their food and fluid for 3 days.
Study Type
Observational
Enrollment (Estimated)
50
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jens Rikardt Andersen, MD, MPA
- Phone Number: 004523346654
- Email: jra@nexs.ku.dk
Study Contact Backup
- Name: Julian Askøe Bluming, RD
- Phone Number: 004591568528
- Email: lft190@alumni.ku.dk
Study Locations
-
-
-
Herlev, Denmark, 2730
- Recruiting
- Herlev Hospital, Dept Nephrology
-
Contact:
- Julian Askøe Bluming, RD
- Phone Number: 004591568528
- Email: lft190@alumni.ku.dk
-
Sub-Investigator:
- Julian A Bluming, RD
-
-
Capital Region
-
Herlev, Capital Region, Denmark, 2730
- Active, not recruiting
- Copenhagen University Hospital - Herlev
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Patients with chronic kidney disease stage 4-5
Description
Inclusion Criteria:
- A glomerular filtration rate of <30 ml ml/min/1.73m2
- 18 years and above
Exclusion Criteria:
None
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Comparison of diatery photograph method with weighted records.
Time Frame: 3 days
|
The intake of calcium and phosphate assesed by the 24 hour photos and the 72 hour weighing of food and fluid items will be compared.
|
3 days
|
|
Calcium and phosphate balance in relation to the stage of kidney disease
Time Frame: 3 days
|
Measured by the diatery intake of calcium and phosphate in relation to the urinary calcium and phosphate excretion
|
3 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Urinary Calcium
Time Frame: 3 days
|
mmol/day
|
3 days
|
|
Urinary phosphate
Time Frame: 3 days
|
mmol/day
|
3 days
|
|
Calcium intake total and the distribution of vegetarian and animal sources
Time Frame: 3 days
|
mg/day
|
3 days
|
|
Phosphate intake total and the distribution of vegetarian and animal sources
Time Frame: 3 days
|
mg/day
|
3 days
|
|
sodium intake total and the distribution of vegetarian and animal sources
Time Frame: 3 days
|
mg/day
|
3 days
|
|
Energy intake
Time Frame: 3 days
|
Kcal/day
|
3 days
|
|
Protein intake
Time Frame: 3 days
|
g/day
|
3 days
|
|
Fat intake
Time Frame: 3 days
|
g/day
|
3 days
|
|
Fluid intake
Time Frame: 3 days
|
ml/day
|
3 days
|
|
Plasma phosphate
Time Frame: 3 days
|
mmol/l
|
3 days
|
|
Plasma calcium
Time Frame: 3 days
|
mmol/l
|
3 days
|
|
Urinary creatinine
Time Frame: 3 days
|
mmol/day
|
3 days
|
|
Urinary urea
Time Frame: 3 days
|
mmol/day
|
3 days
|
|
Urinary sodium
Time Frame: 3 days
|
mmol/day
|
3 days
|
|
Plasma FGF23
Time Frame: 3 days
|
mmol/l
|
3 days
|
|
P-calcium P- phosphate product
Time Frame: 3 days
|
Can be calculated by multiplying plasma calcium and plasma phosphate
|
3 days
|
|
plasma 25-OH-Vitamin D
Time Frame: 3 days
|
nmol/l
|
3 days
|
|
plasma PTH
Time Frame: 3 days
|
pmol/l
|
3 days
|
|
Plasma Albumin
Time Frame: 3 days
|
g/dl
|
3 days
|
|
eGFR
Time Frame: 3 days
|
ml/min/1.73m2
|
3 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Jens Rikardt Andersen, MD, MPA, Assoc Prof, University of Copenhagen
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 15, 2025
Primary Completion (Estimated)
May 15, 2026
Study Completion (Estimated)
May 15, 2029
Study Registration Dates
First Submitted
December 17, 2025
First Submitted That Met QC Criteria
December 17, 2025
First Posted (Actual)
December 31, 2025
Study Record Updates
Last Update Posted (Actual)
December 31, 2025
Last Update Submitted That Met QC Criteria
December 17, 2025
Last Verified
December 1, 2025
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Urogenital Diseases
- Endocrine System Diseases
- Bone Diseases
- Musculoskeletal Diseases
- Pathologic Processes
- Nutrition Disorders
- Male Urogenital Diseases
- Kidney Diseases
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Chronic Disease
- Disease Attributes
- Metabolic Diseases
- Renal Insufficiency
- Bone Diseases, Metabolic
- Parathyroid Diseases
- Avitaminosis
- Deficiency Diseases
- Malnutrition
- Rickets
- Calcium Metabolism Disorders
- Vitamin D Deficiency
- Hyperparathyroidism, Secondary
- Hyperparathyroidism
- Pathological Conditions, Signs and Symptoms
- Nutritional and Metabolic Diseases
- Renal Insufficiency, Chronic
- Chronic Kidney Disease-Mineral and Bone Disorder
Other Study ID Numbers
- H-25039131
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
Currently no plans for sharing
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on CKD
-
California Institute of Renal ResearchRecruitingCKD Stage 4 | CKD Stage 5 | CKD Stage 3United States
-
Centenario Hospital Miguel HidalgoNot yet recruitingExercise | CKD Stage 3 | Symbiotic | Diet Interventions | CKD Stage 1 | CKD Stage 2Mexico
-
Assiut UniversityNot yet recruiting
-
NYU Langone HealthNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
University of MinnesotaIndiana UniversityNot yet recruiting
-
Institute of Medicinal Biotechnology, Chinese Academy...Weifang People's Hospital; Shenzhen HighTide Biopharmaceutical Ltd.Not yet recruiting
-
Medical Components, Inc dba MedCompSyneos Health; Veeva SystemsWithdrawnESRD | CKDSpain, United States
-
Nabiqasim Industries (Pvt) LtdNot yet recruiting
-
Ain Shams UniversityMisr International University; October 6 UniversityCompletedCKD Anemia in Stable Dialysis Patients | CKD AnemiaEgypt